Baoping Chang

机构：First Affiliated Hospital of Henan University of Science and Technology

发表论文 10 篇 · 总被引 112 次 · h-index 6

代表论文

• KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial (2024 · Cell Reports Medicine · 被引 44)
• Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study (2023 · International Journal of Gynecological Cancer · 被引 28)
• Softened Microstructure and Properties of 12 μm Thick Rolled Copper Foil (2022 · Materials · 被引 10)
• A phase 2, open-label, multicenter study to evaluate the efficacy, safety, and tolerability of KN046 in combination with chemotherapy in subjects with advanced non-small cell lung cancer. (2021 · Journal of Clinical Oncology · 被引 9)
• IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial (2025 · Med · 被引 7)
• 357 GLS-010 (Zimberelimab), a novel fully human anti-PD-1 mAb in chinese patients with recurrent/metastatic cervical cancer: results from a multicenter, open-label, single-arm phase II trial (2020 · International Journal of Gynecological Cancer · 被引 7)